Advertisement

Abstract

Heterozygous somatic mutations in the genes encoding isocitrate dehydrogenase-1 and -2 (IDH1 and IDH2) were recently discovered in human neoplastic disorders. These mutations disable the enzymes’ normal ability to convert isocitrate to 2-ketoglutarate (2-KG) and confer on the enzymes a new function: the ability to convert 2-KG to d-2-hydroxyglutarate (D-2-HG). We have detected heterozygous germline mutations in IDH2 that alter enzyme residue Arg140 in 15 unrelated patients with d-2-hydroxyglutaric aciduria (D-2-HGA), a rare neurometabolic disorder characterized by supraphysiological levels of D-2-HG. These findings provide additional impetus for investigating the role of D-2-HG in the pathophysiology of metabolic disease and cancer.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (kranendijk.som.pdf)

References

1
Parsons D. W., et al., An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807 (2008); published online 4 September 2008 (10.1126/science.1164382).
2
Dang L., et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739 (2009).
3
Ward P. S., et al., The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225 (2010).
4
Yan H., et al., IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765 (2009).
5
Kranendijk M., et al., Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria. Hum. Mutat. 31, 279 (2010).
6
Struys E. A., et al., Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am. J. Hum. Genet. 76, 358 (2005).
7
Struys E. A., Verhoeven N. M., Brunengraber H., Jakobs C., Investigations by mass isotopomer analysis of the formation of D-2-hydroxyglutarate by cultured lymphoblasts from two patients with D-2-hydroxyglutaric aciduria. FEBS Lett. 557, 115 (2004).
8
Aghili M., Zahedi F., Rafiee E., Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol. 91, 233 (2009).
9
Steenweg M. E., et al., An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: A genotype-phenotype study. Hum. Mutat. 31, 380 (2010).

(0)eLetters

eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter.

Log In to Submit a Response

No eLetters have been published for this article yet.

Information & Authors

Information

Published In

Science
Volume 330 | Issue 6002
15 October 2010

Article versions

You are viewing the most recent version of this article.

Submission history

Received: 21 May 2010
Accepted: 11 August 2010
Published in print: 15 October 2010

Permissions

Request permissions for this article.

Authors

Affiliations

Martijn Kranendijk*
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, 1081 HV Amsterdam, Netherlands.
Eduard A. Struys
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, 1081 HV Amsterdam, Netherlands.
Emile van Schaftingen
Laboratory of Physical Chemistry, de Duve Institute, Universite Catholique de Louvain, xxxx Louvain, Belgium.
K. Michael Gibson
Department of Biological Sciences, Michigan Technological University, Houghton, MI 49931, USA.
Warsha A. Kanhai
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, 1081 HV Amsterdam, Netherlands.
Marjo S. van der Knaap
Department of Child Neurology, VU University Medical Center Amsterdam, xxxx Amsterdam, Netherlands.
Jeanne Amiel
Département de Génétique et INSERM U-781, Hôpital Necker, Université Paris Descartes, xxxx Paris, France.
Neil R. Buist
Department of Pediatrics and Department of Medical Genetics, Oregon Health and Science University, Portland, OR 9xxxx, USA.
Anibh M. Das
Paediatrische Stoffwechselmedizin, Hannover Medical School, xxxx Hannover, Germany.
Johannis B. de Klerk
Department Metabolic Diseases, ErasmusMC/Sophia Childrens Hospital, xxxx Rotterdam, Netherlands.
Annette S. Feigenbaum
Division of Clinical and Metabolic Genetics, The Hospital for Sick Children and University of Toronto, Toronto, ON xxxxx, Canada.
Dorothy K. Grange
Division of Genetics and Genomic Medicine, Department of Pediatrics St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO xxxxx, USA.
Floris C. Hofstede
Department of Metabolic Diseases, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, xxxx Utrecht, Netherlands.
Elisabeth Holme
Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, University of Gothenburg, xxxx Gothenburg, Sweden.
Edwin P. Kirk
Department of Medical Genetics, Sydney Children’s Hospital, Sydney, NSW xxxxx, Australia.
Stanley H. Korman
Department of Human Genetics and Metabolic Diseases, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
Eva Morava
Department of Pediatrics, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, Netherlands.
Andrew Morris
Great Ormond Street Hospital for Children National Health Service Trust, London xxxx, UK.
Jan Smeitink
Institute for Genetic and Metabolic Disease, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, Netherlands.
Rám N. Sukhai
General Pediatrics, Leiden University Medical Center, xxxx Leiden, Netherlands.
Hilary Vallance
Department of Pathology and Laboratory Medicine, BC Children’s Hospital, University of British Columbia, Vancouver, BC xxxxx, Canada.
Cornelis Jakobs [email protected]
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, 1081 HV Amsterdam, Netherlands.
Gajja S. Salomons
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, 1081 HV Amsterdam, Netherlands.

Notes

*
The list of all affiliations is available in the supporting online material.
To whom correspondence should be addressed. E-mail: [email protected]

Metrics & Citations

Metrics

Article Usage

Altmetrics

Citations

Cite as

Export citation

Select the format you want to export the citation of this publication.

Cited by

  1. L2hgdh Deficiency Accumulates l -2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration , Molecular and Cellular Biology, 37, 8, (2023).https://doi.org/10.1128/MCB.00492-16
    Crossref
  2. Biallelic variants in OGDH encoding oxoglutarate dehydrogenase lead to a neurodevelopmental disorder characterized by global developmental delay, movement disorder, and metabolic abnormalities, Genetics in Medicine, 25, 2, (100332), (2023).https://doi.org/10.1016/j.gim.2022.11.001
    Crossref
  3. D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase, Cell Reports, 42, 2, (112067), (2023).https://doi.org/10.1016/j.celrep.2023.112067
    Crossref
  4. Disruption of mitochondrial bioenergetics, calcium retention capacity and cell viability caused by D-2-hydroxyglutaric acid in the heart, Biochimie, 207, (153-164), (2023).https://doi.org/10.1016/j.biochi.2022.11.004
    Crossref
  5. Nutrigenomics in the management and prevention of metabolic disorders, Role of Nutrigenomics in Modern-day Healthcare and Drug Discovery, (209-274), (2023).https://doi.org/10.1016/B978-0-12-824412-8.00006-0
    Crossref
  6. IDH1/2 mutations in acute myeloid leukemia , Blood Research, 57, 1, (13-19), (2022).https://doi.org/10.5045/br.2021.2021152
    Crossref
  7. Obstacles to Glioblastoma Treatment Two Decades after Temozolomide, Cancers, 14, 13, (3203), (2022).https://doi.org/10.3390/cancers14133203
    Crossref
  8. Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma, Biomedicines, 10, 2, (246), (2022).https://doi.org/10.3390/biomedicines10020246
    Crossref
  9. Emerging cellular themes in leukodystrophies, Frontiers in Cell and Developmental Biology, 10, (2022).https://doi.org/10.3389/fcell.2022.902261
    Crossref
  10. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer, Nature Reviews Cardiology, 19, 6, (414-425), (2022).https://doi.org/10.1038/s41569-022-00698-6
    Crossref
  11. See more
Loading...

View Options

Check Access

Log in to view the full text

AAAS ID LOGIN

AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.

Log in via OpenAthens.
Log in via Shibboleth.

More options

Register for free to read this article

As a service to the community, this article is available for free. Login or register for free to read this article.

Purchase this issue in print

Buy a single issue of Science for just $15 USD.

View options

PDF format

Download this article as a PDF file

Download PDF

Full Text

FULL TEXT

Media

Figures

Multimedia

Tables

Share

Share

Share article link

Share on social media